ライフサイエンスコーパス: retroperitoneal

1 A strong emphasis has been placed on retroperitoneal access, which is inherently more attract

2 th the benefits of endoscopic techniques and retroperitoneal access.

3 stemic mastocytosis were hepatosplenomegaly, retroperitoneal adenopathy, periportal adenopathy, mesen

4 per day for 16 weeks) on gene expression in retroperitoneal adipose and heart tissue from obese, dia

5 erator-activated receptor-gamma decreased in retroperitoneal adipose tissue from obese versus lean mi

6 l had a higher amount of intraperitoneal and retroperitoneal adipose tissue mass.

7 cency outlining the bladder, consistent with retroperitoneal air.

8 ved in a colon cancer patient with extensive retroperitoneal and cervical metastasis.

9 ated [3H]2-deoxyglucose (2-DG) uptake by the retroperitoneal and epididymal white tissue and IBAT, bu

10 rticularly in regard to performing posterior retroperitoneal and subtotal adrenalectomies.

11 underwent resection of residual mediastinal, retroperitoneal, and inguinal cancer, respectively.

12 -size distributions in epididymal, inguinal, retroperitoneal, and mesenteric fat under both weight ga

13 edictive value of masses of intraperitoneal, retroperitoneal, and subcutaneous abdominal adipose tiss

14 P-2 mRNA by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal,

15 From January 1981 to September 1995, 2340 retroperitoneal aortoiliac reconstructions were performe

16 sigmoid colon was mobilized by a posterior, retroperitoneal approach and the colon was divided intra

17 The retroperitoneal approach for abdominal aortic reconstruc

18 tive of this article is to determine whether retroperitoneal approach for aortic surgery has certain

19 The retroperitoneal approach has been shown to decrease oper

20 The retroperitoneal approach offers certain physiologic adva

21 The retroperitoneal approach permits direct access to the re

22 al advantages of the extended posterolateral retroperitoneal approach, the authors have expanded its

23 We advocate a thoracoabdominal retroperitoneal approach, which provides safe control of

24 d pyeloplasty can be performed by a trans or retroperitoneal approach.

25 e performed by either a transperitoneal or a retroperitoneal approach.

26 bin drop >/=4 g/dL, intracranial hemorrhage, retroperitoneal bleed, or transfusion) among 99 200 pati

27 ]; P < 0.001) but an increase in the odds of retroperitoneal bleeding (OR, 1.57 [CI, 1.12 to 2.20]; P

28 disseminated histoplasmosis, complicated by retroperitoneal bleeding and leading to death, in a pati

29 access-site bleeding, access-site hematoma, retroperitoneal bleeding, or any vascular complication r

30 small increase in the more serious risk for retroperitoneal bleeding.

31 The stents were found in the retroperitoneal cavity connecting both veins in all anim

32 vein was punctured transvenously through the retroperitoneal cavity.

33 und in sacrococcygeal, gonadal, mediastinal, retroperitoneal, cervicofacial and intracranial location

34 , cystic degeneration, necrosis, hemorrhage, retroperitoneal collaterals, and renal vein thrombosis.

35 A normal retromesenteric-retroperitoneal D3 located between the superior mesenter

36 e the feasibility of US in demonstrating the retroperitoneal D3.

37 cal necrosectomy consisted of video-assisted retroperitoneal debridement or, if not feasible, laparot

38 Retroperitoneal dedifferentiated liposarcoma was associa

39 has had a favorable impact on the extent of retroperitoneal disease and has significantly reduced th

40 In assessing group A patients, the bulk of retroperitoneal disease at presentation had no influence

41 ogic stage II patients with low-volume (pN1) retroperitoneal disease increased significantly (40% bef

42 The incidence of retroperitoneal disease outside the boundaries of five m

43 32%) patients had evidence of extratemplate retroperitoneal disease, depending on the boundaries of

44 f transgastric puncture, balloon dilatation, retroperitoneal drainage, and necrosectomy.

45 No patient had omental or retroperitoneal edema alone.

46 curred alone in 26 (38%) and with omental or retroperitoneal edema in 40 (58%) of the 69 patients wit

47 Mesenteric, omental, and retroperitoneal edema occur commonly in patients with ci

48 nteric edema and the presence of omental and retroperitoneal edema.

49 e called a peri-rectal oncologic gateway for retroperitoneal endoscopic single site surgery (PROGRESS

50 In 6 patients who underwent retroperitoneal exploration, 1-4 SNs were identified usi

51 in all patients using the gamma probe before retroperitoneal exploration.

52 ailable literature suggests that survival of retroperitoneal fasciitis is possible with prompt debrid

53 ctose, leading to SNS activation in IBAT and retroperitoneal fat and enhanced GLUT4 expression.

54 ssion of GLUT4 was more abundant in IBAT and retroperitoneal fat from glucose- and fructose-fed anima

55 nterscapular brown adipose tissue (IBAT) and retroperitoneal fat increased in response to glucose and

56 subcutaneous abdominal, intraperitoneal, and retroperitoneal fat masses using magnetic resonance imag

57 iated fat that appears to originate from the retroperitoneal fat outside and posterior to the interna

58 Inguinal, epididymal, and retroperitoneal fat pads weighed less in the running tha

59 nuclear proteins from BAT, inguinal fat, and retroperitoneal fat tissue interact with the CRE2 motif

60 alysis was performed using the variations of retroperitoneal fat Ucp1 mRNA expression in progeny of g

61 ympathectomy abolished the GLUT4 response in retroperitoneal fat, but was without effect on GLUT4 in

62 Sharp debridement of the retroperitoneal fat, the right anterior rectus sheath, a

63 with concomitant necrosis of peritoneal and retroperitoneal fat.

64 romosome 19 were linked to Ucp1 induction in retroperitoneal fat.

65 curred in white fat tissues, particularly in retroperitoneal fat.

66 lucose disposal rate than intraperitoneal or retroperitoneal fat; however, NIDDM patients were more i

67 , but increased it in epididymal, though not retroperitoneal, fat.

68 This case report describes a retroperitoneal fetus in fetu and discusses its clinical

69 Simian retroperitoneal fibromatosis (RF) is a vascular fibropro

70 We previously identified retroperitoneal fibromatosis-associated herpesvirus (RFH

71 The complete sequence of retroperitoneal fibromatosis-associated herpesvirus Maca

72 wo closely related macaque homologs of KSHV, retroperitoneal fibromatosis-associated herpesvirus-Maca

73 hout SG lesions (RD-nonSG), and IgG4-related retroperitoneal fibrosis (RF).

74 Idiopathic retroperitoneal fibrosis (RPF) is a rare disease.

75 Idiopathic retroperitoneal fibrosis (RPF), reviewed herein, is a ra

76 dominal periaortitis cases, and a portion of retroperitoneal fibrosis cases are all caused by IgG4-re

77 d in the literature as being associated with retroperitoneal fibrosis include the use of beta-blockin

78 Retroperitoneal fibrosis is a disease process with an un

79 Retroperitoneal fibrosis is a rare disease, typically wi

80 In this study, a case of retroperitoneal fibrosis is reported, in which the patie

81 apy is a potentially effective treatment for retroperitoneal fibrosis that warrants evaluation in ran

82 e patient presented with typical symptoms of retroperitoneal fibrosis, along with some atypical vascu

83 f presumed cardiac involvement of idiopathic retroperitoneal fibrosis, otherwise known as Ormond dise

84 dominal aortic aneurysm or periaortitis, and retroperitoneal fibrosis.

85 istletoe sign could be helpful in diagnosing retroperitoneal fibrosis.

86 ndromes and one patient with an IgG4-related retroperitoneal fibrosis.

87 t might be a characteristic manifestation of retroperitoneal fibrosis.

88 ssociation of beta-blocker usage, lupus, and retroperitoneal fibrosis.

89 be an effective treatment for patients with retroperitoneal fibrosis.

90 s, inflammatory abdominal aortic aneurysm or retroperitoneal fibrosis.

91 stranding, peritumoral fat planes obscured, retroperitoneal fluid (subcapsular vs extracapsular), as

92 ngs may explain the observed distribution of retroperitoneal fluid collections from diaphragm to pelv

93 s, followed by perinephric fat stranding and retroperitoneal fluid for reviewers 1 and 2, respectivel

94 ed in body weight, fat pad mass (omental and retroperitoneal), food intake, serum insulin, hepatic tr

95 Retroperitoneal ganglioneuroma is a rare bening tumor, g

96 CASE REPORT: We present a case of retroperitoneal ganglioneuroma that mimicked renal mass

97 st-PCI was defined as: arterial access site, retroperitoneal, gastrointestinal, or genitourinary blee

98 Retroperitoneal GCT should be treated in a similar fashi

99 T magnetic resonance (MR) neurography-guided retroperitoneal genitofemoral nerve (GFN) blocks are saf

100 Results In 26 subjects, 30 retroperitoneal GFN blocks were performed.

101 a rank order of responsiveness of ovarian > retroperitoneal > subcutaneous.

102 patients to serious complications including retroperitoneal haemorrhage and impaired renal function.

103 nts judged to be unrelated to treatment (one retroperitoneal haemorrhage, one subarachnoid haemorrhag

104 He had a primary retroperitoneal hemangiopericytoma removed in 1982 and w

105 The six most common injuries included retroperitoneal hematoma (n = 13) and injuries in the sp

106 nce, clinical features, and risk factors for retroperitoneal hematoma (RPH) after percutaneous corona

107 At necropsy, a small retroperitoneal hematoma along the stent and minimal int

108 uding pseudoaneurysm, arteriovenous fistula, retroperitoneal hematoma, femoral artery thrombosis, sur

109 computed tomography (CT) in 82 patients with retroperitoneal hemorrhage (n = 24), inflammation (n = 3

110 f the pattern of ecchymosis seen in cases of retroperitoneal hemorrhage.

111 imodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment o

112 Retroperitoneal histology and RFS did not change over ti

113 Surgical repair was effected through a retroperitoneal incision enabling vascular control.

114 False-negative findings were retroperitoneal injury, bowel injury, and intraperitonea

115 We show that knockdown of CD24 increases retroperitoneal invasion and liver metastasis of pancrea

116 xenograft model, and that BART also prevents retroperitoneal invasion and liver metastasis of pancrea

117 b) inhibition of uPAR inhibits tumor growth, retroperitoneal invasion, and hepatic metastasis of huma

118 without gemcitabine on primary tumor growth, retroperitoneal invasion, and hepatic metastasis.

119 hepatic metastasis and completely inhibited retroperitoneal invasion.

120 C2 LOH in four lymph nodes from a woman with retroperitoneal LAM.

121 esponses occurred in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarc

122 normal smooth muscle and a series of primary retroperitoneal leiomyosarcomas.

123 ce following complete resection of a primary retroperitoneal liposarcoma between July 1982 and Decemb

124 currence after complete resection of primary retroperitoneal liposarcoma is a common clinical problem

125 Of 177 patients with primary retroperitoneal liposarcoma operated on for curative int

126 s used to identify 177 patients with primary retroperitoneal liposarcoma treated between July 1982 an

127 WDLS and DDLS, the majority of patients with retroperitoneal liposarcoma will eventually have recurre

128 s with completely resected locally recurrent retroperitoneal liposarcoma.

129 ction are prognostic for survival in primary retroperitoneal liposarcoma.

130 e in a large series of patients with primary retroperitoneal liposarcoma.

131 dependent prognostic factors for survival in retroperitoneal liposarcoma.

132 Secondary retroperitoneal LN dissection revealed a high number of

133 Secondary retroperitoneal LN dissection was done in 32 of 147 pati

134 patients with dedifferentiated histology or retroperitoneal location.

135 patients with primary extremity, truncal, or retroperitoneal LS treated between 1982 and 2005 were id

136 Retroperitoneal lymph node (LN) involvement is common in

137 y patients with disseminated GCTs have large retroperitoneal lymph node (RPLN) metastases that may ca

138 We evaluated men undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for NSG

139 Some authors recommend postchemotherapy retroperitoneal lymph node dissection (PC-RPLND), wherea

140 han reported in men who have a nerve-sparing retroperitoneal lymph node dissection (RPLND) because mo

141 the outcome of patients managed primarily by retroperitoneal lymph node dissection (RPLND) or chemoth

142 r betaHCG, betaHCG more than 100 ng/mL, redo retroperitoneal lymph node dissection (RPLND), and secon

143 needed to facilitate decision making between retroperitoneal lymph node dissection (RPLND), primary c

144 with adjuvant radiotherapy, chemotherapy, or retroperitoneal lymph node dissection (RPLND).

145 Retroperitoneal lymph node dissection also appears to be

146 mmended measuring AFP and hCG shortly before retroperitoneal lymph node dissection and at the start o

147 or clinical stage I testis cancer has led to retroperitoneal lymph node dissection being performed mo

148 Minimally invasive retroperitoneal lymph node dissection carries safety and

149 Retroperitoneal lymph node dissection continues to play

150 interest in surveillance rather than primary retroperitoneal lymph node dissection for clinical stage

151 lk sac tumor and 5% embryonal carcinoma, and retroperitoneal lymph node dissection for clinical stage

152 apy and away from radiation, and the role of retroperitoneal lymph node dissection in disseminated no

153 l clinically relevant studies on the role of retroperitoneal lymph node dissection in early and advan

154 The role of retroperitoneal lymph node dissection in postorchiectomy

155 odified templates, a bilateral nerve-sparing retroperitoneal lymph node dissection is the treatment o

156 Retroperitoneal lymph node dissection remains a prominen

157 chemotherapy-resistant disease ('desperation retroperitoneal lymph node dissection'), although the re

158 3%) of 27 patients initially managed without retroperitoneal lymph node dissection.

159 in approximately 40% of all postchemotherapy retroperitoneal lymph node dissections (PC-RPLND).

160 Modified template retroperitoneal lymph node dissections (RPLND) have beco

161 chemotherapy and five had undergone previous retroperitoneal lymph node dissections (RPLNDs).

162 Patients in arm B (n = 60) had only retroperitoneal lymph node involvement (27 patients [45%

163 iver (n = 6), presacral soft tissue (n = 3), retroperitoneal lymph nodes (n = 2), spleen (n = 2), and

164 uptake in the prostatic bed or in pelvic or retroperitoneal lymph nodes had longer PCa-specific surv

165 emotherapy followed by surgical resection of retroperitoneal lymph nodes that contained metastatic ma

166 e bladder (UBC) metastatic to the pelvic and retroperitoneal lymph nodes was treated with gemcitabine

167 disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function and

168 ad metastatic adenocarcinoma in the resected retroperitoneal lymph nodes, and none had retroperitonea

169 10% had metastatic carcinoma in the resected retroperitoneal lymph nodes, and none of those patients

170 CT in biopsy of small abdominal, pelvic and retroperitoneal lymph nodes.

171 ons; surveillance, adjuvant chemotherapy, or retroperitoneal lymph-node dissection.

172 managed with surveillance, chemotherapy, or retroperitoneal lymphadenectomy (RPLND) with similar sur

173 In experienced hands, laparoscopic retroperitoneal lymphadenectomy for renal cell cancer is

174 trast, patients with elevated markers before retroperitoneal lymphadenectomy have a high rate of rela

175 rom the addition of a distal gastrectomy and retroperitoneal lymphadenectomy to a pylorus-preserving

176 ddition of a distal gastrectomy and extended retroperitoneal lymphadenectomy to a standard pancreatic

177 arker elevation after orchiectomy and before retroperitoneal lymphadenectomy was a significant indepe

178 andard resection plus distal gastrectomy and retroperitoneal lymphadenectomy).

179 odenectomy (including distal gastrectomy and retroperitoneal lymphadenectomy).

180 andard resection plus distal gastrectomy and retroperitoneal lymphadenectomy).

181 s later, surveillance imaging identified new retroperitoneal lymphadenopathy and a large right pelvic

182 ging studies revealed progressive pelvic and retroperitoneal lymphadenopathy, and the patient enrolle

183 han that for active RPF or malignant RPF and retroperitoneal malignant neoplasm.

184 group I, 25 patients with malignant RPF and retroperitoneal malignant neoplasm; group II, 16 patient

185 Several centers have reported high rates of retroperitoneal margin positivity after pancreaticoduode

186 same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area.

187 med and histopathological examination of the retroperitoneal mass revealed GN.

188 rgical approaches enable excellent access to retroperitoneal masses and synchronous excision of ipsil

189 tratemplate metastasis for men with residual retroperitoneal masses less than 1, 1 to 2, 2 to 5, and

190 Retroperitoneal masses were present in three patients.

191 tho DKO mice had significantly (P<0.01) less retroperitoneal, mesenteric, and epididymal fat accumula

192 nseminomatous germ cell tumor had low-volume retroperitoneal metastases (pathologic stage pN1, 1997 t

193 l] v > 100 xnl, P = .02) and the presence of retroperitoneal metastases (yes or no, P = .04).

194 Retroperitoneal metastases were limited to microscopic n

195 oneal metastases, HCG < or = 100 xnl without retroperitoneal metastases, and all patients with HCG mo

196 th EC predominance, as 40 (32.0%) of 125 had retroperitoneal metastases, compared with 26 (15.6%) of

197 Patients grouped by HCG < or = 100 xnl with retroperitoneal metastases, HCG < or = 100 xnl without r

198 At the time of surgery, the retroperitoneal metastasis in the pelvis was confirmed.

199 Retroperitoneal necrotizing fasciitis is an uncommon sof

200 Early diagnosis of retroperitoneal necrotizing fasciitis, wide and repeated

201 onal Animal Care and Use Committee approval, retroperitoneal neuroblastomas were established in mice

202 iotherapy and presence of hepatic, lung, and retroperitoneal nodal metastases were found to be indepe

203 On multivariable analysis, prechemotherapy retroperitoneal nodal size (odds ratio [OR], 1.12; 95% C

204 site of EHD affected survival, with portal, retroperitoneal nodes and multiple sites associated with

205 site of EHD affected survival, with portal, retroperitoneal nodes and multiple sites associated with

206 ed retroperitoneal lymph nodes, and none had retroperitoneal nodes as the only site of lymph node inv

207 ph nodes, and none of those patients had the retroperitoneal nodes as the only site of lymph node inv

208 ance imaging (MRI), metastatic spread to the retroperitoneal nodes on the left side was detected only

209 went surgical resection of a gastric GIST; a retroperitoneal, nonfunctional paraganglioma; and a medi

210 inferior vena cava occlusion, and pain from retroperitoneal or bowel penetration.

211 RT for retroperitoneal or pelvic sarcoma is controversial, and

212 etrospectively compare patients with primary retroperitoneal or pelvic sarcoma treated during 2003-20

213 advanced-modality RT to surgery for primary retroperitoneal or pelvic sarcoma was associated with im

214 r than 16 years, had evidence of testicular, retroperitoneal, or mediastinal non-seminomatous germ ce

215 teric venous system without traversal of any retroperitoneal organs or adjacent vasculature.

216 confirm that the needle did not traverse any retroperitoneal organs or vessels.

217 ear-old patient with the third recurrence of retroperitoneal paraganglioma.

218 Retroperitoneal pathology and relapse rates were compare

219 Predictors of retroperitoneal pathology included an increasing serum A

220 Retroperitoneal pathology revealed germ cell cancer in 5

221 Demonstration of normal retromesenteric-retroperitoneal position of D3 on ultrasound (US) can ru

222 fast and highly accurate tool to confirm the retroperitoneal position of D3.

223 procedure, whereas 21 underwent a posterior retroperitoneal procedure via bilateral incisions.

224 The treatments were surveillance only; retroperitoneal radiotherapy (RT); bleomycin, etoposide,

225 those with type 2 to have proximal biliary, retroperitoneal, renal, or salivary disease (60% vs 0; P

226 RECENT FINDINGS: Retroperitoneal robotic surgery has been successfully ap

227 Retroperitoneal robotic surgery is a relatively new tech

228 nt publications and review our experience of retroperitoneal robotic surgery.

229 ng response characteristics in patients with retroperitoneal (RP) WD/DD liposarcoma treated at The Un

230 rointestinal RR, 2.78; 95% CI, 1.25 to 6.18; retroperitoneal RR, 5.87; 95% CI, 1.63 to 21.12; and int

231 Vascular resection and retroperitoneal safety margin status did not affect dise

232 nostic factors for survival in patients with retroperitoneal sarcoma and suggest that patients with l

233 reated surgically for primary, nonmetastatic retroperitoneal sarcoma during 1982 to 2010 were identif

234 The histologic diversity and rarity of retroperitoneal sarcoma has hampered the ability to pred

235 All imaging features suggested a retroperitoneal sarcoma in the pelvic region with metast

236 Radiation therapy for retroperitoneal sarcoma patients is complex because it r

237 locally advanced or recurrent rectal cancer, retroperitoneal sarcoma, select gynecologic cancers, and

238 herapy in the care of surgical patients with retroperitoneal sarcoma.

239 bility of preoperative radiation therapy for retroperitoneal sarcoma.

240 nt attempted surgical resection of a primary retroperitoneal sarcoma.

241 dent predictor of DSD, LR, and DR in primary retroperitoneal sarcoma.

242 ths vs. 19 months, P = 0.001) and truncal or retroperitoneal sarcomas (39 months vs. 31 months, P = 0

243 Retroperitoneal sarcomas (RPS) are rare tumors composed

244 ients with localized, potentially resectable retroperitoneal sarcomas (RPS).

245 histories of all patients operated upon for retroperitoneal sarcomas between January 1983 and Decemb

246 Primary retroperitoneal sarcomas in the pelvic region are extrem

247 care for patients with localized, resectable retroperitoneal sarcomas is surgical resection with gros

248 ion margin did not predict local control for retroperitoneal sarcomas or fibrosarcomas.

249 rate for other-than-primary fibrosarcoma and retroperitoneal sarcomas, and independently predict dist

250 e shown little efficacy in the management of retroperitoneal sarcomas, making total surgical extirpat

251 e a significant problem in the management of retroperitoneal sarcomas.

252 to the diagnosis, staging, and management of retroperitoneal sarcomas.

253 ansanal NOTES total mesorectal excision with retroperitoneal sigmoid mobilization and coloanal, side-

254 e sarcoma database carrying the diagnosis of retroperitoneal soft tissue sarcoma who were eligible fo

255 not included in the conventional staging of retroperitoneal soft tissue sarcomas (RPS) is essential

256 Retroperitoneal soft tissue sarcomas are rare tumors est

257 Retroperitoneal soft tissue sarcomas are rare tumors.

258 d with long-term survival after resection of retroperitoneal soft tissue sarcomas.

259 ifty-one patients with plaque-like confluent retroperitoneal soft-tissue masses were divided into thr

260 complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10

261 l violation to determine injury to intra- or retroperitoneal solid organs, bowel, mesentery, vascular

262 rinary bladder and metastatic disease in the retroperitoneal space of the pelvis.

263 After exploration of the retroperitoneal space up to the level of the obliterated

264 on that offers the immediate availability of retroperitoneal staging or cytoreductive surgery if nece

265 nd abdomen ( Fig 2 ) revealed periaortic and retroperitoneal stranding.

266 h direct visualization of the needle and all retroperitoneal structures.

267 Retroperitoneal STS are relatively uncommon and constitu

268 Five hundred patients with retroperitoneal STS were admitted and treated between Ju

269 In this study of patients with retroperitoneal STS, stage at presentation, high histolo

270 ique offer an encouraging outlook on robotic retroperitoneal surgery.

271 wing chemotherapy as well as the appropriate retroperitoneal templates to use in the postchemotherapy

272 without significantly affecting the rate of retroperitoneal teratoma (21% v 22%, respectively; P = .

273 of systemic progression and 22% incidence of retroperitoneal teratoma supports RPLND as the preferred

274 .019), but rates of pathologic stage II and retroperitoneal teratoma were unaffected.

275 epresents the largest series of laparoscopic retroperitoneal triple neurectomies for treatment of ing

276 As a primary retroperitoneal tumor, it constitutes only a small perce

277 either large (>10 cm), high-grade or truncal/retroperitoneal tumors should be treated exclusively at

278 brosis - a cause of pain, bowel obstruction, retroperitoneal vascular constriction and right heart fa

279 tumors by virtue of local invasion into the retroperitoneal vessels in the absence of clinically det

280 Retroperitoneal/visceral (RP/V) tumors have a poorer pro

281 emity sarcomas (34% v 41%) and in those with retroperitoneal/visceral sarcomas (29% v 34%).

282 (71 NeoCT patients and 130 Surg patients) or retroperitoneal/visceral sarcomas (34 NeoCT and 74 Surg)

283 ted in profound reductions in epididymal and retroperitoneal WAT mass, without affecting subcutaneous

284 wnregulation of Ip6k1 in murine inguinal and retroperitoneal white adipose tissue (IWAT and RWAT) dep

285 Retroperitoneal white adipose tissue (rWAT) and subcutan

286 ffect on leptin mRNA in either epididymal or retroperitoneal white adipose tissue (WAT) from beta(3)-